Find your situation.
See where it goes.

A commercial director at a mid-size MedTech company. Twelve reps. A product that won every clinical evaluation. Strong evidence. Good relationships with key clinicians. Everything pointed to a successful launch.

Six months in, the revenue curve was flat. The best rep was at 180% of target. The worst was at 40%. Same product. Same training. Same territory structure. The variance was enormous and nobody could explain it. Marketing had produced content the sales team didn't use. Events had generated badge scans sitting in drawers. The distributor was sending optimistic reports and requests for more brochures.

The board was asking what went wrong. The honest answer was that nothing had gone wrong, specifically. Everything had gone wrong, structurally. The product was ready. The messaging wasn't. The sales team was trained on features, not situations. Marketing was treated as a department, not an infrastructure. Finance had never modelled what the launch should return, so nobody knew whether it was actually working or not. The technical file and the sales deck had never met.

A diagnosis that walked the entire commercial chain — positioning, messaging, sales enablement, digital presence, advocate programme, measurement. Not fixing one link. Finding the weakest one.

The full 3 E's programme. Messaging architecture built from customer research, not internal assumptions. A sales playbook with the Five Ps toolkit — what every rep says, how they say it, what they leave behind. Digital content strategy so clinicians had heard of them before the twelve-minute meeting. An advocate programme with eight key clinicians who were already using the product and willing to talk about it.

Conversion improved from 18% to 31%. The sales cycle shortened by three weeks. Qualified enquiries increased by 47%. The variance between best and worst rep narrowed by 60%. Not because the reps changed. Because the system changed.

Another year of the same pattern. More reps hired to compensate. More budget spent on congresses that generated badge scans. The best rep succeeding despite the system. Everyone else failing because of it. Eventually, the board concluding that the product wasn't viable. It was always viable. Nobody set it up to succeed.

The commercial director walked into the next board meeting with a dashboard, not a slide deck. Marketing went from cost centre to the department that could prove pipeline. The sales team stopped telling twelve different product stories and started telling one that worked. The company went from 'the launch that missed forecast' to 'the playbook we use for every launch now.'

A marketing director at a global MedTech subsidiary. Four major congresses per year. Six-figure annual events budget. A stand that looked impressive. Badge scanners that worked overtime. 'Great conversations' noted in the post-event report.

The CFO asked a simple question: what did the events budget deliver to pipeline? The marketing director reached for proxies. Booth visitors. Badge scans. 'Conversations with key opinion leaders.' Social media impressions from the congress hashtag. None of it was pipeline. None of it was revenue. None of it answered the question.

The truth was that nobody had defined success before committing the budget. Nobody had identified the twenty people in the room who actually mattered. Nobody had tracked whether those people had been met, what was discussed, or what happened next. The events were moments in time, not campaigns. Sixty-five thousand on a congress booth, four hundred badges scanned, seven converted to qualified prospects. Nine thousand three hundred per conversation. Nobody measured this because nobody set up the measurement.

A question that reframed everything: 'If you knew in advance that 60% of the people at your stand have no buying authority, would you change how you run the event?'

Beyond the Badge Scan methodology. Define success before committing budget. Identify the twenty decision-makers in the room by name. Build the environment that makes those conversations happen naturally. Staff training on qualification — knowing within ninety seconds whether this person can buy. Pipeline tracking from first meeting through to close. Post-event follow-up within forty-eight hours, not three weeks.

340% ROI demonstrated — for the first time in the company's history, they could prove what events delivered. Decision-maker meeting rate increased 3x. Marketing earned an increased budget allocation as a direct result. The data showed which events were worth attending and which weren't. The portfolio was restructured around evidence, not tradition.

Another year of the same budget, the same approach, the same inability to answer the CFO's question. Eventually, the events budget gets cut because nobody can defend it. The company loses presence at the congresses that actually matter because they couldn't prove the ones that mattered were different from the ones that didn't.

The marketing director stopped defending the events budget and started directing it. They walked into the budget meeting with data, not hope. The CFO went from sceptic to advocate. The events team went from logistics coordinators to pipeline generators. The company discovered that fewer, better events with proper measurement outperformed a busy calendar of untracked appearances.

A CEO of a 40-person diagnostics company. Product established in the UK with strong adoption. The board wanted international expansion. Three markets identified based on a conversation at a congress and a contact who 'knows people in the Middle East.'

The market entry strategy was built on relationships, not data. Nobody had scored the target markets across regulatory burden, reimbursement potential, competitive density, or operational feasibility. The contact in the Middle East turned out to know people, but couldn't build a market — the 'tour guide trap' that derails more international expansions than any other single factor.

The messaging that worked in the UK didn't land. Not because it was wrong — because it was British. The way a UK surgeon talks about a clinical problem is different from how a surgeon in Dubai or Singapore describes the same issue. The company had translated their materials. They hadn't localised them.

A market prioritisation framework that ranked options by data, not gut feel. An honest assessment that two of the three target markets weren't viable in the near term — the regulatory burden didn't justify the reimbursement potential.

Focus on the one market where the numbers worked. Localised messaging built for how clinicians in that market actually make decisions. A distribution partner selection process based on capability, not just connections. The Five Ps toolkit adapted for the local team. An event strategy designed around the two congresses that mattered, not the six the company planned to attend.

Partnerships with major hospital trusts established within six months. The focused approach delivered faster results than the scattered one would have. The second market was entered twelve months later with a proven playbook. The third market was deprioritised entirely based on the data — saving a year of wasted investment.

Money spread across three markets, none of them properly. A country manager in the Middle East sending optimistic reports. Twelve months of runway burned with no traction. Competitors establishing positions in the market that actually mattered while the company was distracted elsewhere.

The CEO stopped making market entry decisions at congress dinners and started making them with a scorecard. The board saw a disciplined international strategy, not an optimistic spreadsheet. The company learned that entering one market properly was worth more than entering three markets hopefully.